YouTube Outage Disrupts Thousands Worldwide as Recommendation System Fails 
Mitsui Kinzoku Stock Surges to Record High After Profit Forecast Upgrade and Dividend Increase 
European IT Hardware Stocks to Watch as Gaming Demand Outpaces Smartphones, Says BofA 
Microsoft Plans $50 Billion AI Investment to Accelerate Growth in the Global South 
Freedom Finance and Binance Join Forces in Digital Assets 
Santos Wins Court Case Over Net Zero and Sustainability Claims 
BlueScope Steel Forecasts Stronger Second-Half Earnings, Shares Rise Above Rejected Buyout Offer 
BHP Group Half-Year Profit Surges as Copper Overtakes Iron Ore on AI-Driven Demand 
Anthropic’s Claude AI Reportedly Used in U.S. Operation to Capture Nicolas Maduro 
Reese’s Peanut Butter Cup Recipe Debate: Hershey Responds as Cocoa Prices Shift 
Goldman Sachs Reportedly Drops Diversity Criteria From Board Candidate Evaluations 
Luxury Stocks Face Volatility as AI Market Swings and Hedge Fund Bets Rattle LVMH and Kering 
AstroTurf Expands Footprint at Colorado as Buffaloes Complete Second Installation in 12 Months 
Federal Court Fines Mobil Oil Australia A$16 Million for Misleading Fuel Claims 
Hedge Funds Cut Nvidia, Amazon and Microsoft Stakes as AI Valuation Concerns Rise 
Yotta to Build $2 Billion AI Data Centre Hub in India with Nvidia Blackwell Ultra Chips 
Starboard Value Targets Tripadvisor Board Overhaul Amid Stock Slump 
REDWOOD CITY, Calif., May 01, 2018 -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced that the Company will report first quarter 2018 financial results and operational highlights on Tuesday, May 8th, 2018. OncoMed will not be conducting a conference call in conjunction with this earnings release.
About OncoMed Pharmaceuticals
OncoMed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics. OncoMed has internally discovered a broad pipeline of investigational drugs intended to address the fundamental biology driving cancer's growth, resistance, recurrence and metastasis. Anti-TIGIT (OMP-313M32), navicixizumab (anti-DLL4/VEGF bispecific, OMP-305B83), and rosmantuzumab (anti-RSPO3, OMP-131R10) are part of OncoMed's strategic alliance with Celgene Corporation. OncoMed is independently developing GITRL-Fc (OMP-336B11), as well as continuing to pursue new drug discovery research. For further information about OncoMed Pharmaceuticals, please see www.oncomed.com.
Investor Relations Contact:
Matthew Beck
Solebury Trout
[email protected]
(646) 378-2933
